---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-23-000079"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:28:42.854359+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience increases authorized common shares from 20M to 100M and expands equity incentive pool

## Summary
- Board and majority stockholders approved incentive plan amendment raising authorized shares to 1,846,883, with automatic 5% annual increases from 2024-2032.
- Charter amendment increases authorized common stock from 20,000,000 to 100,000,000 shares, approved by majority stockholders via written consent on Sept 29, 2023.
- Both actions become effective 20 calendar days after mailing of definitive information statement to stockholders.
- Incentive plan amendment allows grants of stock options, SARs, restricted stock, RSUs, and performance awards.
- Majority stockholders executed written consents on Sept 29, 2023, bypassing stockholder meeting for both amendments.

## SEC filing metadata
- accession: 0001516551-23-000079
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655123000079/0001516551-23-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655123000079/skye-20230929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-23-000079
- JSON: https://secwatch.observer/filing/0001516551-23-000079.json
- Plain text: https://secwatch.observer/filing/0001516551-23-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.